Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis

Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis - Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024507

Enrollment

Registered

2016-10-21

Start date

2011-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

In these patients, who had received SASP/MTX combination therapy for at least 12 weeks, SASP was discontinued, and the patients received MTX monotherapy for the next 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The main inclusion criteria were age 20 years and over, treatment with SASP/MTX combination therapy for at least 12 weeks before entry into this study, and low disease activity

Exclusion criteria

Exclusion criteria: patients who showed poor compliance

Design outcomes

Primary

Measure	Time frame
change of serum MTX concentration	—

Secondary

Measure	Time frame
simplified disease activity index (SDAI) and disease activity score-C reactive protein (DAS28-CRP),levels of matrix metalloproteinase-3 (MMP-3),inflammatory cytokines,questionnaire	—

Countries

Japan

Contacts

Public ContactMorihiro Okada

Japan Community Healthcare Organization Kanazawa Hospital Department of Pharmacy

okada-knz@umin.ac.jp+81-76-252-2200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026